
Please try another search
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Joseph H. Mangan | - | 2025 | Board Advisors |
Chuanhai Cao | - | 2017 | Scientific Advisor |
Elliot L. Hong | - | - | Scientific Advisor |
Howard W. Gutman | 67 | 2007 | Strategic Board Advisor |
Richard K. Prins | 68 | 2007 | Independent Chairman of the Board |
James A. Saunders | - | 2015 | Scientific Advisor |
Claudia Grimaldi | 53 | 2018 | VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director |
James Moran | 80 | 2022 | Independent Director |
Terry L. Lierman | 77 | 2024 | Independent Director |
Pablo Arbelaez | - | - | Scientific Advisor |
Terry McAuliffe | - | 2024 | Board Advisor |
Jeffrey L. Cummings | 76 | - | Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review